Healthcare provider lists at Swiss Exchange

Sandoz, the global leader in generic and biosimilar medicines announced its share trading on the SIX Swiss Exchange as an independent company.

According to Sandoz Philippines country manager Michael Paul Batilllano, the healthcare company will be continuing its commitment to provide Filipinos with medical innovations that tackle the challenges of the healthcare landscape.

A spin-off from Novartis, the healthcare company has been present in the Philippines since 2022, across all major therapeutic areas, and employs a total of 179 associates.

Now an independent company, Sandoz will continue to be a pioneer in providing access for patients and introducing biosimilars as a revolutionary development in ensuring accessible medicines.

Sandoz Philippines’ parent company is included in key SIX market indices and has an investment-grade credit rating that gives it a strong competitive position. It is well placed for continued profitable growth as a standalone global leader and European champion in generic and biosimilar medicines.

“As an independent company, Sandoz will be fully enabled to deliver on its purpose-driven strategy, which targets sustainable leadership in the growing and critical generics and biosimilars industry,”said Sandoz CEO Richard Saynor.